Homes and Property | Home Page

Patent battle defeat hits GSK

12 April 2012

GLAXOSMITHKLINE fell 31p to 1699p on Thursday night after losing a legal patent battle in the US which could allow Israel's Teva Pharmaceuticals rights to launch a rival to GSK's best-selling antibiotic Augmentin.

GSK is to appeal against the ruling as it and other drug giants face a wave of actions by companies keen to launch cheap generic versions of big sellers.

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Sign up you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy notice .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in

MORE ABOUT

Intel Corporation
Medicine
Pharmaceuticals
Selling